Login Register Cart 0
Generic placeholder image

Recent Patents on Biotechnology

Editor-in-Chief

ISSN (Print): 1872-2083
ISSN (Online): 2212-4012

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Comparison of Five Escherichia coli Strains to Achieve the Maximum Yield of a Recombinant Immunotoxin Consisting of an Antibody against VEGF Conjugated with MAP30 Toxin in a Benchtop Bioreactor

Author(s): Mina Zarei and Mohammad Hossein Morowvat*

Volume 18, Issue 1, 2024

Published on: 04 April, 2023

Page: [52 - 62] Pages: 11

DOI: 10.2174/1872208317666230316111554

Price: $65

conference banner
Abstract

Background: Cancer is among the leading causes of death worldwide, imposing high costs on the health systems of all societies. Extensive biological studies are required to discover appropriate therapies. Escherichia coli has long been regarded as one of the main biotechnological bio-factories to produce recombinant protein-based therapeutics. In the present study, five strains of E. coli were compared to achieve the maximum production of a previously designed recombinant immunotoxin-carrying MAP30 toxin against VEGF-overexpressed cancer cells in a benchtop bioreactor.

Methods: The recombinant immunotoxin coding gene sequence was extracted from the NCBI database. The host used to produce the recombinant immunotoxin were five E. coli strains of BL21 (DE3), DH5α, SHuffle®T7, XL1-Blue, and Rosetta-gamiTM (DE3). CaCl2 method was used for bacterial transformation. Bacterial growth measurements were performed using optical density measurements at 600 nm. The immunotoxin production was measured using SDS-PAGE analysis. The best-producing strain was cultivated in a 10-L benchtop stirred tank bioreactor. Recent patents on this field were also studied.

Results: The results demonstrated that the BL21 (DE3) strain had the highest expression of recombinant protein in comparison to other strains. Moreover, the cell growth of E. coli BL21 (DE3) and SHuffle®T7 strains before transformation in the LB medium, were significantly higher in comparison to other strains. Additionally, the transformation of Rosettagami was associated with decreased cell proliferation. The transformation of the XL1-Blue strain did not effect cell growth. Analysis of the growth kinetics demonstrated appropriate proliferation of the transformed BL21 (DE3) cells in the laboratory benchtop bioreactor.

Conclusions: Based on the results of this study, the BL21 (DE3) strain could be used as a suitable host for the production of the recombinant immunotoxin against VEGF in stirred tank bioreactor, which can be employed for the treatment of tumors. Yet, its precise mechanism must be explored in extensive studies.

« Previous Next »
Graphical Abstract

[1]
Teicher BA, Chari RVJ. Antibody conjugate therapeutics: Challenges and potential. Clin Cancer Res 2011; 17(20): 6389-97.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-1417] [PMID: 22003066]
[2]
Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006; 17(1): 114-24.
[http://dx.doi.org/10.1021/bc0502917] [PMID: 16417259]
[3]
Teicher B. Antibody-drug conjugate targets. Curr Cancer Drug Targets 2009; 9(8): 982-1004.
[http://dx.doi.org/10.2174/156800909790192365] [PMID: 20025606]
[4]
Kim KM, McDonagh CF, Westendorf L, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther 2008; 7(8): 2486-97.
[http://dx.doi.org/10.1158/1535-7163.MCT-08-0388] [PMID: 18723494]
[5]
McDonagh CF, Kim KM, Turcott E, et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther 2008; 7(9): 2913-23.
[http://dx.doi.org/10.1158/1535-7163.MCT-08-0295] [PMID: 18790772]
[6]
Chari RVJ. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 2008; 41(1): 98-107.
[http://dx.doi.org/10.1021/ar700108g] [PMID: 17705444]
[7]
Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 2018; 32(8): 1768-77.
[http://dx.doi.org/10.1038/s41375-018-0210-1] [PMID: 30030507]
[8]
Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol 2009; 157(2): 220-33.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00190.x] [PMID: 19459844]
[9]
Goldmacher VS, Kovtun YV. Antibody–drug conjugates: Using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv 2011; 2(3): 397-416.
[http://dx.doi.org/10.4155/tde.10.98] [PMID: 22834009]
[10]
Hosseininejad-Chafi M, Alirahimi E, Ramezani B, et al. In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin. Iran J Basic Med Sci 2022; 25(1): 27-31.
[PMID: 35656448]
[11]
Shi Z, Pang K, Yang W, et al. Antitumor mechanism of MAP30 in bladder cancer T24 cells, and its potential toxic effects in mice. Cell Mol Biol 2020; 66(1): 42-8.
[http://dx.doi.org/10.14715/cmb/2019.66.1.7] [PMID: 32359382]
[12]
Chan DW, Yung MMH, Chan YS, et al. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis. Pharmacol Res 2020; 161: 105157.
[http://dx.doi.org/10.1016/j.phrs.2020.105157] [PMID: 32814169]
[13]
Lee-Huang S, Huang PL, Chen HC, et al. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene 1995; 161(2): 151-6.
[http://dx.doi.org/10.1016/0378-1119(95)00186-A] [PMID: 7665070]
[14]
Schreiber CA, Wan L, Sun Y, Lu L, Krey LC, Lee-Huang S. The antiviral agents, MAP30 and GAP31, are not toxic to human spermatozoa and may be useful in preventing the sexual transmission of human immunodeficiency virus type 1. Fertil Steril 1999; 72(4): 686-90.
[http://dx.doi.org/10.1016/S0015-0282(99)00302-7] [PMID: 10521111]
[15]
Schweickert PG, Cheng Z. Application of genetic engineering in biotherapeutics development. J Pharmaceut Innov 2020; 15: 232-54.
[http://dx.doi.org/10.1007/s12247-019-09411-6]
[16]
Yin J, Li G, Ren X, Herrler G. Select what you need: A comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J Biotechnol 2007; 127(3): 335-47.
[http://dx.doi.org/10.1016/j.jbiotec.2006.07.012] [PMID: 16959350]
[17]
Collins JH, Young EM. Genetic engineering of host organisms for pharmaceutical synthesis. Curr Opin Biotechnol 2018; 53: 191-200.
[http://dx.doi.org/10.1016/j.copbio.2018.02.001] [PMID: 29471209]
[18]
Becker J, Wittmann C. From systems biology to metabolically engineered cells - an omics perspective on the development of industrial microbes. Curr Opin Microbiol 2018; 45: 180-8.
[http://dx.doi.org/10.1016/j.mib.2018.06.001] [PMID: 30172106]
[19]
Kaur J, Kumar A, Kaur J. Strategies for optimization of heterologous protein expression in E. coli: Roadblocks and reinforcements. Int J Biol Macromol 2018; 106: 803-22.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.08.080] [PMID: 28830778]
[20]
Marisch K, Bayer K, Cserjan-Puschmann M, Luchner M, Striedner G. Evaluation of three industrial Escherichia coli strains in fed-batch cultivations during high-level SOD protein production. Microb Cell Fact 2013; 12(1): 58.
[http://dx.doi.org/10.1186/1475-2859-12-58] [PMID: 23758670]
[21]
Morowvat MH, Babaeipour V, Rajabi-Memari H, Vahidi H, Maghsoudi N. Overexpression of recombinant human beta interferon (rhINF-β) in periplasmic space of Escherichia coli. Iran J Pharm Res 2014; 13 (Suppl.): 151-60.
[PMID: 24711841]
[22]
Heiat M, Hashemi Yeganeh H, Alavian SM, Rezaie E. Immunotoxins immunotherapy against hepatocellular carcinoma: A promising prospect. Toxins (Basel) 2021; 13(10): 719.
[http://dx.doi.org/10.3390/toxins13100719] [PMID: 34679012]
[23]
Sanz L, Ibáñez-Pérez R, Guerrero-Ochoa P, Lacadena J, Anel A. Antibody-based immunotoxins for colorectal cancer therapy. Biomedicines 2021; 9(11): 1729.
[http://dx.doi.org/10.3390/biomedicines9111729] [PMID: 34829955]
[24]
Shajari S, Farajollahi MM, Behdani M, Tarighi P. Production and conjugation of truncated recombinant diphtheria toxin to VEGFR-2 specific nanobody and evaluation of its cytotoxic effect on PC-3 cell line. Mol Biotechnol 2022; 64(11): 1218-26.
[http://dx.doi.org/10.1007/s12033-022-00485-1] [PMID: 35478310]
[25]
Khalesi R, Salimian J, Nazarian S, Ehsaei Z, Amini N, Moazzeni SM. Production and purification of heat-labile toxin of enterotoxigenic Escherichia coli and its detection by GM1 gangelioside receptor-ELISA based method. J Arak Univ Med Sci 2012; 15(1): 35-42.
[26]
Safari E, Zavaran HA, Hassan Z, Khajeh K, Ardestani MS, Baradaran B. Cytotoxic effect of immunotoxin containing the truncated form of Pseudomonas exotoxin A and anti-VEGFR2 on HUVEC and MCF-7 cell lines. Cell J 2014; 16(2): 203-10.
[PMID: 24567937]
[27]
Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103(11): 1820-8.
[http://dx.doi.org/10.1016/S0161-6420(96)30420-X] [PMID: 8942877]
[28]
Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13(16): 1845-57.
[http://dx.doi.org/10.2174/092986706777585059] [PMID: 16842197]
[29]
Ciomber A, Smagur A, Mitrus I, et al. Antitumor effects of recombinant antivascular protein ABRaA-VEGF121 combined with IL-12 gene therapy. Arch Immunol Ther Exp 2014; 62(2): 161-8.
[http://dx.doi.org/10.1007/s00005-013-0259-5] [PMID: 24220932]
[30]
Xie J, Deng C, Gu X, Cai Y. Recombinant immunotoxin and preparation method and application therof. CN108676095A, 2018.
[31]
Molloy M, Pechenick D, Powers G, Rothstein J, Snyder L. Anti-human VISTA antibodies and use therof. AU2022252828A1, 2022.
[32]
Dimitrov DS. Engineered antibody constant domain molecules. US10358481B2, 2019.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy